Guillain-Barré syndrome in children

Journal of Child Neurology

Volumn 19, Issue 3, 2004, Pages 191-200

  Sladky, John T ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNOGLOBULIN;

ALLERGIC NEUROPATHY; ARTIFICIAL VENTILATION; CHILD; CONVALESCENCE; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNIZATION; INCIDENCE; INDUSTRIALIZATION; MORBIDITY; PARALYSIS; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY FAILURE; REVIEW;

ADOLESCENT; ANIMALS; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DISEASE MODELS, ANIMAL; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNIZATION, PASSIVE; INCIDENCE; INFANT; PLASMAPHERESIS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; VACCINES;

EID: 2342444462     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (136)

1. Ho TW, Mishu B, Li CY, et al: Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and antiglycolipid antibodies. Brain 1995;118(Pt 3):597-605.
2. Hafer-Macko C, Hsieh ST, Li CY, et al: Acute motor axonal neuropathy: An antibody-mediated attack on axolemma. Ann Neurol 1996;40:635-644.
3. Griffin JW, Li CY, Ho TW, et al: Guillain-Barré syndrome in northern China. The spectrum of neuropathological changes in clinically defined cases. Brain 1995;118(Pt 3):577-595.
4. McKhann GM, Cornblath DR, Ho T, et al: Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China. Lancet 1991;338:593-597.
5. McKhann GM, Cornblath DR, Griffin JW, et al: Acute motor axonal neuropathy: A frequent cause of acute flaccid paralysis in China. Ann Neurol 1993;33:333-342.
6. Bradshaw DY, Jones HR Jr: Guillain-Barré syndrome in children: Clinical course, electrodiagnosis, and prognosis. Muscle Nerve 1992;15:500-506.
7. Evans OB, Vedanarayanan V: Guillain-Barré syndrome. Pediatr Rev 1997;18:10-16.
8. Hughes RA, Rees JH: Clinical and epidemiologic features of Guillain-Barré syndrome. J Infect Dis 1997;176(Suppl 2):S92-S98.
9. Hung KL, Wang HS, Liou WY, et al: Guillain-Barré syndrome in children: A cooperative study in Taiwan. Brain Dev 1994;16:204-208.
10. Jones HR Jr: Guillain-Barré syndrome in children. Curr Opin Pediatr 1995;7:663-668.
11. Jones HR: Childhood Guillain-Barré syndrome: Clinical presentation, diagnosis, and therapy. J Child Neurol 1996;11:4-12.
12. Oostvogel PM, Spaendonck MA, Hirasing RA, van Loon AM: Surveillance of acute flaccid paralysis in The Netherlands, 1992-94. Bull World Health Organ 1998;76:55-62.
13. Paradiso G, Tripoli J, Galicchio S, Fejerman N: Epidemiological, clinical, and electrodiagnostic findings in childhood Guillain-Barré syndrome: A reappraisal. Ann Neurol 1999; 46:701-707.
14. Asbury AK: Diagnostic considerations in Guillain-Barré syndrome. Ann Neurol 1981;9(Suppl):1-5.
15. Brown WF, Feasby TE: Conduction block and denervation in Guillain-Barré polyneuropathy. Brain 1984;107(Pt 1):219-239.
16. Brown WF, Snow R: Patterns and severity of conduction abnormalities in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1991;54:768-774.
17. Ropper AH, Wijdicks EF, Shahani BT: Electrodiagnostic abnormalities in 113 consecutive patients with Guillain-Barré syndrome. Arch Neurol 1990;47:881-887.
18. Sumner AJ: The physiological basis for symptoms in Guillain-Barré syndrome. Ann Neurol 1981;9(Suppl):28-30.
19. Hughes RA, Hadden RD, Gregson NA, Smith KJ: Pathogenesis of Guillain-Barré syndrome. J Neuroimmunol 1999;100:74-97.
20. Alam TA, Chaudhry V, Cornblath DR: Electrophysiological studies in the Guillain-Barré syndrome: Distinguishing subtypes by published criteria. Muscle Nerve 1998;21:1275-1279.
21. Chowdhury D, Arora A. Axonal Guillain-Barré syndrome: A critical review. Acta Neurol Scand 2001;103:267-277.
22. Zhang X, Zhang Z, Tang X: Guillain-Barré syndrome in six cities and provinces of northern China: Is it a new entity? Chin Med J (Engl) 1995;108:734-738.
23. Ho TW, Hsieh ST, Nachamkin I, et al: Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection. Neurology 1997;48:717-724.
24. Lu JL, Sheikh KA, Wu HS, et al: Physiologic-pathologic correlation in Guillain-Barré syndrome in children. Neurology 2000;54:33-39.
25. Fisher M: An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 1956;255:57-65.
26. Asbury AK: New concepts of Guillain-Barré syndrome. J Child Neurol 2000;15:183-191.
27. Toyka KV: Eighty three years of the Guillain-Barré syndrome: Clinical and immunopathologic aspects, current and future treatments. Rev Neurol (Paris) 1999;155:849-856.
28. Ter Bruggen JP, van der Meche FG, de Jager AE, Polman CH: Ophthalmoplegic and lower cranial nerve variants merge into each other and into classical Guillain-Barré syndrome. Muscle Nerve 1998;21:239-242.
29. Ropper AH: Miller Fisher syndrome and other acute variants of Guillain-Barré syndrome. Baillieres Clin Neurol 1994;3:95-106.
30. O'Leary CP, Willison HJ: Autoimmune ataxic neuropathies (sensory ganglionopathies). Curr Opin Neurol 1997;10:366-370.
31. Jamal GA, MacLeod WN: Electrophysiologic studies in Miller Fisher syndrome. Neurology 1984;34:685-688.
32. Guiloff RJ: Peripheral nerve conduction in Miller Fisher syndrome. J Neurol Neurosurg Psychiatry 1977;40:801-809.
33. Willison HJ, Veitch J, Paterson G, Kennedy PG: Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside. J Neurol Neurosurg Psychiatry 1993;56:204-206.
34. Chiba A, Kusunold S, Kuwata S, et al: HLA and anti-GQ1b IgG antibody in Miller Fisher syndrome and Guillain-Barré syndrome. J Neuroimmunol 1995;61:85-88.
35. Carpo M, Pedotti R, Lolli F, et al: Clinical correlate and fine specificity of anti-GQ1b antibodies in peripheral neuropathy. J Neurol Sci 1998;155:186-191.
36. Kusunoki S, Chiba A, Kanazawa I: Anti-GQ1b IgG antibody is associated with ataxia as well as ophthalmoplegia. Muscle Nerve 1999;22:1071-1074.
37. Willison HJ, O'Hanlon GM: The immunopathogenesis of Miller Fisher syndrome. J Neuroimmunol 1999;100:3-12.
38. Visser LH, van der Meche FG, Meulstee J, et al: Cytomegalovirus infection and Guillain-Barré syndrome: The clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barré Study Group. Neurology 1996;47:668-673.
39. Yuki N, Susuki Y, Hirata K: Ataxic Guillain-Barré syndrome with anti-GQ1b antibody: Relation to Miller Fisher syndrome. Neurology 2000;54:1851-1853.
40. Wong V: A neurophysiological study in children with Miller Fisher syndrome and Guillain-Barré syndrome. Brain Dev 1997;19: 197-204.
41. Jones HR Jr: Guillain-Barré syndrome: Perspectives with infants and children. Semin Pediatr Neurol 2000;7:91-102.
42. Farkkila M, Kinnunen E, Weckstrom P. Survey of Guillain-Barré syndrome in southern Finland. Neuroepidemiology 1991; 10:236-241.
43. Olive JM, Castillo C, Castro RG, de Quadros CA. Epidemiologic study of Guillain-Barré syndrome in children < 15 years of age in Latin America. J Infect Dis 1997;175(Suppl 1):S160-S164.
44. Rantala H, Uhari M, Niemela M: Occurrence, clinical manifestations, and prognosis of Guillain-Barré syndrome. Arch Dis Child 1991;66:706-708; discussion 708-709.
45. Boucquey D, Sindic CJ, Lamy M, et al: Clinical and serological studies in a series of 45 patients with Guillain-Barré syndrome. J Neurol Sci 1991;104:56-63.
46. Grose C, Henle W, Henle G, Feorino PM: Primary Epstein-Barr-virus infections in acute neurologic diseases. N Engl J Med 1975;292:392-395.
47. Jacobs BC, Rothbarth PH, van der Meche FG, et al: The spectrum of antecedent infections in Guillain-Barré syndrome: A case-control study. Neurology 1998;51:1110-1115.
48. Kusunoki S, Chiba A, Hitoshi S, et al: Anti-Gal-C antibody in autoimmune neuropathies subsequent to mycoplasma infection. Muscle Nerve 1995;18:409-413.
49. Meseguer MA, Aparicio M, Calvo A, et al: Mycoplasma pneumoniae antigen detection in Guillain-Barré syndrome. Eur J Pediatr 1998;157:1034.
50. Rees JH, Soudain SE, Gregson NA, Hughes RA: Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med 1995;333:1374-1379.
51. Rees JH, Thompson RD, Smeeton NC, Hughes RA: Epidemiological study of Guillain-Barré syndrome in south east England. J Neurol Neurosurg Psychiatry 1998;64:74-77.
52. Asbury AK: Guillain-Barré syndrome: Historical aspects. Ann Neurol 1990;27(Suppl):S2-S6.
53. Marks JS, Halpin TJ: Guillain-Barré syndrome in recipients of A/New Jersey influenza vaccine. JAMA 1980;243:2490-2494.
54. Safranek TJ, Lawrence DN, Kurland LT, et al: Reassessment of the association between Guillain-Barré syndrome and receipt of swine influenza vaccine in 1976-1977: Results of a two-state study. Expert Neurology Group. Am J Epidemiol 1991;133:940-951.
55. Korinthenberg R, Monting JS: Natural history and treatment effects in Guillain-Barré syndrome: A multicentre study. Arch Dis Child 1996;74:281-287.
56. Kleyweg RP, van der Meche FG, Loonen MC, et al: The natural history of the Guillain-Barré syndrome in 18 children and 50 adults. J Neurol Neurosurg Psychiatry 1989;52:853-856.
57. Khatri A, Pearlstein L: Pain in Guillain-Barré syndrome. Neurology 1997;49:1474.
58. Mikati MA, DeLong GR: Childhood Guillain-Barré syndrome masquerading as a protracted pain syndrome. Arch Neurol 1985;42:839.
59. Moulin DE, Hagen N, Feasby TE, et al: Pain in Guillain-Barré syndrome. Neurology 1997;48:328-331.
60. Nguyen DK, Agenarioti-Belanger S, Vanasse M: Pain and the Guillain-Barré syndrome in children under 6 years old. J Pediatr 1999;134:773-776.
61. Ropper AH, Shahani BT: Pain in Guillain-Barré syndrome. Arch Neurol 1984;41:511-514.
62. Alexander JP Jr, Baden L, Pallansch MA, Anderson LJ: Enterovirus 71 infections and neurologic disease - United States, 1977-1991. J Infect Dis 1994;169:905-908.
63. Cornblath DR: Electrophysiology in Guillain-Barré syndrome. Ann Neurol 1990;27(Suppl):S17-S20.
64. Cornblath DR, Mellits ED, Griffin JW, et al: Motor conduction studies in Guillain-Barré syndrome: Description and prognostic value. Ann Neurol 1988;23:354-359.
65. Miller RG, Peterson GW, Daube JR, Albers JW: Prognostic value of electrodiagnosis in Guillain-Barré syndrome. Muscle Nerve 1988;11:769-774.
66. Dalakas MC: Basic aspects of neuroimmunology as they relate to immunotherapeutic targets: Present and future prospects. Ann Neurol 1995;37(Suppl 1):S2-S13.
67. Hahn AF: [Acquired demyelinating neuropathies]. Rev Prat 2000;50:724-730.
68. Hartung HP, Pollard JD, Harvey GK, Toyka KV: Immunopathogenesis and treatment of the Guillain-Barré syndrome - Part II. Muscle Nerve 1995;18:154-164.
69. Hartung HP, Pollard JD, Harvey GK, Toyka KV. Immunopathogenesis and treatment of the Guillain-Barré syndrome - Part I. Muscle Nerve 1995;18:137-153.
70. Rostami AM: Pathogenesis of immune-mediated neuropathies. Pediatr Res 1993;88(Suppl):S90-S94.
71. Rostami AM: Guillain-Barré syndrome: Clinical and immunological aspects. Springer Semin Immunopathol 1995;17:29-42.
72. Van Der Meche FG: The Guillain-Barré syndrome; pathogenesis and treatment. Rev Neurol (Paris) 1996;152:355-358.
73. Asbury AK, Amason BG, Adams RD: The inflammatory lesion in idiopathic polyneuritis: Its role in pathogenesis. Medicine (Baltimore) 1969;48:173-186.
74. Feasby TE, Hahn AF, Brown WF, et al: Severe axonal degeneration in acute Guillain-Barré syndrome: Evidence of two different mechanisms? J Neurol Sci 1993;116:185-192.
75. Griffin JW, Li CY, Macko C, et al: Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barré syndrome. J Neurocytol 1996;25:33-51.
76. Griffin JW, Li CY, Ho TW, et al: Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann Neurol 1996;39:17-28.
77. Hafer-Macko CE, Sheikh KA, Li CY, et al: Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 1996;39:625-635.
78. Hughes R, Atkinson P, Coates P, et al: Sural nerve biopsies in Guillain-Barré syndrome: Axonal degeneration and macrophage-associated demyelination and absence of cytomegalovirus genome. Muscle Nerve 1992;15:568-575.
79. Yuki N: Anti-ganglioside antibody and neuropathy; Review of our research. J Peripher Nerv Syst 1998;3:3-18.
80. Yuki N, Odaka M, Hirata K: Acute ophthalmoparesis (without ataxia) associated with anti-GQ1b IgG antibody: Clinical features. Ophthalmology 2001;108:196-200.
81. Suzuki T, Chiba A, Kusunoki S, et al: Anti-GQ1b ganglioside antibody and ophthalmoplegia of undetermined cause. Br J Ophthalmol 1998;82:916-918.
82. Susuki K, Yuki N, Hirata K: Fine specificity of anti-GQ1b IgG and clinical features. J Neurol Sci 2001;185:5-9.
83. Rees JH, Gregson NA, Hughes RA: Anti-ganglioside antibodies in patients with Guillain-Barré syndrome and Campylobacter jejuni infection. J Infect Dis 1995;172:605-606.
84. Oomes PG, Jacobs BC, Hazenberg MP, et al: Anti-GM1 IgG antibodies and Campylobacter bacteria in Guillain-Barré syndrome: Evidence of molecular mimicry. Ann Neurol 1995;38:170-175.
85. Kuwabara S, Yuki N, Koga M, et al: IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barré syndrome. Ann Neurol 1998;44:202-208.
86. Chiba A, Kusunoki S, Obata H, et al: Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome. Brain Res 1997;745:32-36.
87. Ho TW, Willison HJ, Nachamkin I, et al: Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome. Ann Neurol 1999;45:168-173.
88. Ogawara K, Kuwabara, S, Mori M, et al: Axonal Guillain-Barré syndrome: Relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol 2000;48:624-631.
89. Koski CL, Chou DK, Jungalwala FB: Anti-peripheral nerve myelin antibodies in Guillain-Barré syndrome bind a neutral glycolipid of peripheral myelin and cross-react with Forssman antigen. J Clin Invest 1989;84:280-287.
90. Constantinescu CS, Hilliard B, Fujioka T, et al: Pathogenesis of neuroimmunologic diseases. Experimental models. Immunol Res 1998;17:217-227.
91. Rostami AM: P2-reactive T cells in inflammatory demyelination of the peripheral nerve. J Infect Dis 1997;176(Suppl 2):S160-S163.
92. Hahn AF, Feasby TE, Lovgren D: Antigalactocerebroside antibody increases demyelination in adoptive transfer experimental allergic neuritis. Muscle Nerve 1993;16:1174-1180.
93. Sharief MK, McLean B, Thompson EJ: Elevated serum levels of tumor necrosis factor-alpha in Guillain-Barré syndrome. Ann Neurol 1993; 33:591-596.
94. Sharief MK, Ingram DA, Swash M: Circulating tumor necrosis factor-alpha correlates with electrodiagnostic abnormalities in Guillain-Barré syndrome. Ann Neurol 1997;42:68-73.
95. Sivieri S, Ferrarini AM, Lolli F, et al: Cytokine pattern in the cerebrospinal fluid from patients with GBS and CIDP. J Neurol Sci 1997;147:93-95.
96. Creange A, Belec L, Clair B, et al: Circulating transforming growth factor beta 1 (TGF-beta1) in Guillain-Barré syndrome: Decreased concentrations in the early course and increase with motor function. J Neurol Neurosurg Psychiatry 1998;64:162-165.
97. Creange A, Belec L, Clair B, et al: Circulating tumor necrosis factor (TNF)-alpha and soluble TNF-alpha receptors in patients with Guillain-Barré syndrome. J Neuroimmunol 1996;68:95-99.
98. Exley AR, Smith N, Winer JB: Tumour necrosis factor-alpha and other cytokines in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1994;57:1118-1120.
99. Jander S, Stoll G: Interleukin-18 is induced in acute inflammatory demyelinating polyneuropathy. J Neuroimmunol 2001;114:253-258.
100. Ossege LM, Sindern E, Voss B, Malin JP: Expression of TNFalpha and TGFbeta1 in Guillain-Barré syndrome: Correlation of a low TNFalpha-/TGFbeta1-mRNA ratio with good recovery and signs for immunoregulation within the cerebrospinal fluid compartment. Eur J Neurol 2000;7:17-25.
101. Dalakas MC: Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: Present status and practical therapeutic guidelines. Muscle Nerve 1999;22:1479-1497.
102. Di Marco R, Khademi M, Wallstrom E, et al: Amelioration of experimental allergic neuritis by sodium fusidate (fusidin): Suppression of IFN-gamma and TNF-alpha and enhancement of IL-10. J Autoimmun 1999;13:187-195.
103. Koski CL: Mechanisms of Schwann cell damage in inflammatory neuropathy. J Infect Dis 1997;176(Suppl 2):S169-S172.
104. Kiefer R, Kieseier BC, Stoll G, Hartung HP: The role of macrophages in immune-mediated damage to the peripheral nervous system. Prog Neurobiol 2001;64:109-127.
105. Lisak RP, Skundric D, Bealmear B, Ragheb S: The role of cytokines in Schwann cell damage, protection, and repair. J Infect Dis 1997;176(Suppl 2):S173-S179.
106. Redford EJ, Smith KJ, Gregson NA, et al: A combined inhibitor of matrix metalloproteinase activity and tumour necrosis factor-alpha processing attenuates experimental autoimmune neuritis. Brain 1997;120(Pt 10):1895-1905.
107. Zhu J, Bai XF, Mix E, Link H: Cytokine dichotomy in peripheral nervous system influences the outcome of experimental allergic neuritis: Dynamics of mRNA expression for IL-1 beta, IL-6, IL-10, IL-12, TNF-alpha, TNF-beta, and cytolysin. Clin Immunol Immunopathol 1997;84:85-94.
108. The prognosis and main prognostic indicators of Guillain-Barré syndrome. A multicentre prospective study of 297 patients. The Italian Guillain-Barré Study Group. Brain 1996; 119(Pt 6):2053-2061.
109. Briscoe DM, McMenamin JB, O'Donohoe NV: Prognosis in Guillain-Barré syndrome. Arch Dis Child 1987;62:733-735.
110. Manners PJ, Murray KJ: Guillain-Barré syndrome presenting with severe musculoskeletal pain. Acta Paediatr 1992;81:1049-1051.
111. Jackman NL, Klig JE: Lower extremity pain in a three year old: Manifestations of Guillain-Barré syndrome. Pediatr Emerg Care 1998;14:272-274.
112. Pentland B, Donald SM: Pain in the Guillain-Barré syndrome: A clinical review. Pain 1994;59:159-164.
113. Wong BL, deGrauw T, Fogelson MH: Pain in pediatric Guillain-Barré syndrome: Case report. J Child Neurol 1998; 13:184-185.
114. Bansal BC, Sood AK, Jain SK: Dysautonomia in Guillain Barré syndrome. J Assoc Physicians India 1987;35:417-419.
115. Durocher A, Servais B, Caridroix M, et al: Autonomic dysfunction in the Guillain-Barré syndrome. Hemodynamic and neurobiochemical studies. Intensive Care Med 1980;6:3-6.
116. Levy RL: Panautonomic dysfunction and Guillain-Barré syndrome. JAMA 1980;243:1895-1896.
117. McLeod JG: Autonomic dysfunction in peripheral nerve disease. J Clin Neurophysiol 1993;10:51-60.
118. Dalakas MC: Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 2002;59(Suppl):S12-S21.
119. Kieseier BC, Clements JM, Pischel HB, et al: Matrix metalloproteinases MMP-9 and MMP-7 are expressed in experimental autoimmune neuritis and the Guillain-Barré syndrome. Ann Neurol 1998;43:427-434.
120. Murwani R, Armati P: Peripheral nerve fibroblasts as a source of IL-6, TNFalpha and IL-1 and their modulation by IFNgamma. J Neurol Sci 1998;161:99-109.
121. Previtali SC, Archelos JJ, Hartung HP: Expression of integrins in experimental autoimmune neuritis and Guillain-Barré syndrome. Ann Neurol 1998;44:611-621.
122. Epstein MA, Sladky JT: The role of plasmapheresis in childhood Guillain-Barré syndrome. Ann Neurol 1990;28:65-69.
123. Jansen PW, Perkin RM, Ashwal S: Guillain-Barré syndrome in childhood: Natural course and efficacy of plasmapheresis. Pediatr Neurol 1993;9:16-20.
124. Khatri BO, Flamini JR, Baruah JK, et al: Plasmapheresis with acute inflammatory polyneuropathy. Pediatr Neurol 1990;6:17-19.
125. Lamont PJ, Johnston HM, Berdoukas VA: Plasmapheresis in children with Guillain-Barré syndrome. Neurology 1991; 41:1928-1931.
126. al-Qudah AA: Immunoglobulins in the treatment of Guillain-Barré syndrome in early childhood. J Child Neurol 1994;9:178-180.
127. Abd-Allah SA, Jansen PW, Ashwal S, Perkin RM: Intravenous immunoglobulin as therapy for pediatric Guillain-Barré syndrome. J Child Neurol 1997;12:376-380.
128. Kanra G, Ozon A, Vajsar J, et al: Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. Eur J Paediatr Neurol 1997;1:7-12.
129. Reisin RC, Pociecha J, Rodriguez E, et al: Severe Guillain-Barré syndrome in childhood treated with human immune globulin. Pediatr Neurol 1996;14:308-312.
130. Shahar E, Murphy EG, Roifman CM: Benefit of intravenously administered immune serum globulin in patients with Guillain-Barré syndrome. J Pediatr 1990;116:141-144.
131. Shahar E, Shorer Z, Roifman CM, et al: Immune globulins are effective in severe pediatric Guillain-Barré syndrome. Pediatr Neurol 1997;16:32-36.
132. Visser LH, Schmitz PI, Meulstee J, et al: Prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barré Study Group. Neurology 1999; 53:598-604.
133. Appropriate number of plasma exchanges in Guillain-Barré syndrome. The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Ann Neurol 1997;41:298-306.
134. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Lancet 1997;349:225-230.
135. Creange A, Chazaud B, Sharshar T, et al: Inhibition of the adhesion step of leukodiapedesis: A critical event in the recovery of Guillain-Barré syndrome associated with accumulation of proteolytically active lymphocytes in blood. J Neuroimmunol 2001;114:188-196.
136. Kieseier BC, Seifert T, Giovannoni G, Hartung HP: Matrix metalloproteinases in inflammatory demyelination: Targets for treatment. Neurology 1999;53:20-25.